Article
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
The New England journal of medicine - 6 Jun 2013
Legendre C M, Licht C, Muus P, Greenbaum L A, Babu S, Bedrosian C, Bingham C, Cohen D J, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman R R, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin N S, Trivelli A, Zimmerhackl L B, Goodship T, Loirat C
Abstract excerpt
BACKGROUND: Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels of hematologic measures but does not treat the underlying systemic disease. METHODS: We conducted two prospective phase 2 trials in which patients with atypical hemolytic-uremic syndrome who were 12...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.